Folgen

  • 41. Selling wrecked cars to the entire world

    41. Selling wrecked cars to the entire world
    Feb 8 2026
    For our forty-first episode, we're asking a question: what happens after the car crash? [pause] I mean after the tow trucks have come and the insurance claims have been filed. What happens to the cars that are too damaged to be repaired, the ones the insurance company calls a "total loss"? Well, they enter a hidden, multi-billion dollar ecosystem, a massive global marketplace that gives these wrecked vehicles a second life. And that marketplace is dominated by one company. We are talking about Copart.

    When you hear the name Copart ($CPRT), you probably think of a massive, sprawling junkyard—an auction house for wrecked and salvaged cars. On the surface, it seems like a gritty, industrial business focused on selling damaged vehicles.
    But the real story behind Copart is that it's a technology-driven logistics platform with a nearly impenetrable competitive moat. The company is the indispensable partner for the insurance industry. When a car is declared a total loss, Copart steps in to collect, process, and auction the vehicle on its patented online platform to a global network of buyers. This two-sided network of insurance sellers and licensed buyers creates a powerful flywheel that is almost impossible for competitors to replicate. This has made it one of the market's greatest long-term compounders, but it often trades at a premium valuation.
    We're sifting through the salvage to determine if Copart's dominant business model can continue to drive growth and justify its high price tag, or if this stock is due for a wreck.




    Created with love by Emil Lazzaroni
    2 new episodes per week, until I can find good companies to hold forever.

    This is not in any way, shape or form financial advice. You are the sole responsible for the action you take after listening to any of my content.

    Always consult a professional before investing.
    Mehr anzeigen Weniger anzeigen
    9 Min.
  • 40. Saving your Good Boy is a Big Business

    40. Saving your Good Boy is a Big Business
    Feb 4 2026
    For our fortieth episode, we're talking about a part of our families that often has four legs. [pause] We’re talking about our pets. The trend is undeniable: we've elevated our pets from the backyard to cherished members of the family. We'll spend almost anything to keep them healthy. Today's company is the "Pfizer for your pet." It's the global leader in the medicines, vaccines, and treatments that our veterinarians rely on every single day. We are talking about Zoetis.

    When you hear the name Zoetis ($ZTS), you might know it as the former animal health division of Pfizer, the largest company in the world dedicated to medicines and vaccines for pets and livestock. It's the dominant leader in a niche corner of the healthcare sector.
    But the real story behind Zoetis's incredible success isn't just about animal medicine; it's about the powerful and durable "humanization of pets" megatrend. As owners increasingly treat their pets as members of the family, spending on their health and wellness becomes essential and recession-resistant. This has turned Zoetis into a defensive growth powerhouse with a wide competitive moat, serving both the companion animal and livestock markets. But with the stock consistently trading at a premium valuation, is all the good news already priced in?
    We're checking up on the health of this investment to determine if Zoetis can continue to justify its premium price tag and remain a best-in-breed holding for a long-term portfolio.


    Created with love by Emil Lazzaroni
    2 new episodes per week, until I can find good companies to hold forever.

    This is not in any way, shape or form financial advice. You are the sole responsible for the action you take after listening to any of my content.

    Always consult a professional before investing.
    Mehr anzeigen Weniger anzeigen
    9 Min.
  • 39. From an online bookstore to Mag7 Olympus

    39. From an online bookstore to Mag7 Olympus
    Feb 1 2026
    For our thirty-ninth episode, we're exploring a company that is, for millions of people, the front door to the internet. The one website where you can buy a book, a battery, a banana, and a blockbuster movie, and have it on your doorstep tomorrow. But what if I told you that this colossal retail empire... [pause] isn't actually their most profitable business? Not even close. The real money machine hiding inside this company is something most of its customers have never even heard of. We are talking about the two-headed giant... Amazon.

    When you hear the name Amazon ($AMZN), you think of the "everything store"—the global e-commerce titan that delivers packages to your door with incredible speed. For most people, Amazon is the undisputed king of online retail, a massive, low-margin business focused on selection, price, and convenience.


    But the real story and the overwhelming profit engine of the company isn't in the cardboard boxes; it's in the cloud. Amazon Web Services (AWS) is the dominant leader in cloud computing, providing the digital infrastructure for a massive portion of the internet. This fantastically profitable, high-growth division is what truly funds the entire Amazon empire. Amazon is a cloud computing juggernaut disguised as a retail store. But with competition in the cloud intensifying and regulators scrutinizing its retail dominance, can the giant maintain its momentum?
    We're opening the box to analyze if Amazon's high-margin AWS business can continue to fuel its growth or if the company is facing its toughest challenges yet on multiple fronts.



    Created with love by Emil Lazzaroni
    2 new episodes per week, until I can find good companies to hold forever.

    This is not in any way, shape or form financial advice. You are the sole responsible for the action you take after listening to any of my content.

    Always consult a professional before investing.
    Mehr anzeigen Weniger anzeigen
    10 Min.
  • 38. We understand disease and treat it

    38. We understand disease and treat it
    Jan 28 2026
    For our thirty-eighth episode, we're exploring a company that has been at the forefront of the fight against cancer for decades. A company that built its empire on a unique, two-pillar strategy that is perfectly suited for the future of healthcare. They don't just want to sell you the cure; they want to sell the test that tells you if the cure will work. It’s a story of visionary acquisitions and world-class science. We are talking about the Swiss giant... Roche.

    When you hear the name Roche ($RHHBY), you think of a global pharmaceutical powerhouse, a Swiss giant renowned for its leadership in developing cancer treatments. For decades, it has been a defensive cornerstone in portfolios, known for its deep scientific expertise and a vast portfolio of life-saving medicines.


    But the real story and strategic advantage of Roche lie in its unique dual structure. It is a world leader in not just pharmaceuticals but also in-vitro diagnostics. This powerful combination allows Roche to champion "personalized healthcare"—they can develop a diagnostic test to identify which patients will benefit most from a specific drug, and then provide that targeted therapy. This integrated model creates a formidable competitive moat. However, like all pharma giants, Roche is in a constant race against the patent cliff, with blockbuster drugs facing biosimilar competition.


    We're analyzing the data to see if Roche's synergistic approach and powerful R&D pipeline are enough to outrun patent expirations and diagnose a healthy future for investors.



    Created with love by Emil Lazzaroni
    2 new episodes per week, until I can find good companies to hold forever.

    This is not in any way, shape or form financial advice. You are the sole responsible for the action you take after listening to any of my content.

    Always consult a professional before investing.
    Mehr anzeigen Weniger anzeigen
    9 Min.
  • 37. The art of CRM turned into science

    37. The art of CRM turned into science
    Jan 25 2026
    For our thirty-seventh episode, we’re talking about the company that killed the CD-ROM. The company that looked at the old, clunky, and expensive way businesses bought software and said... [pause] "there has to be a better way." They pioneered the idea that powerful software shouldn't be a product you install, but a service you subscribe to through the internet. They are the undisputed king of their category and the company that truly brought the business world into the cloud. We are talking about Salesforce.

    When you hear the name Salesforce ($CRM), you think of the original cloud software titan, the company that pioneered the Software-as-a-Service (SaaS) model and became the undisputed king of Customer Relationship Management. For years, its story has been one of relentless, trailblazing growth.

    But the real story of Salesforce today is its evolution from a single product into a sprawling, integrated platform. Through massive acquisitions like Slack, MuleSoft, and Tableau, it has transformed into an all-encompassing ecosystem for digital transformation. This growth-by-acquisition strategy has made its platform incredibly sticky, but it has also drawn intense scrutiny from investors who are now demanding profitability over growth-at-any-cost. Can the company successfully pivot from its old playbook?

    We're logging into the cloud to determine if Salesforce can successfully integrate its massive empire and deliver the high-margin, profitable growth that investors now demand.


    Created with love by Emil Lazzaroni
    2 new episodes per week, until I can find good companies to hold forever.

    This is not in any way, shape or form financial advice. You are the sole responsible for the action you take after listening to any of my content.

    Always consult a professional before investing.
    Mehr anzeigen Weniger anzeigen
    10 Min.
  • 36. When treatments means rewriting genetic code

    36. When treatments means rewriting genetic code
    Jan 21 2026
    For our thirty-sixth episode, we're stepping into the world of cutting-edge science. We're talking about a company that is on the front lines in the fight against humanity's toughest diseases—heart disease, cancer, multiple sclerosis. It’s a business built on decades of research, billions of dollars of investment, and the hope of creating blockbuster drugs that can change the world. We are talking about the Swiss giant... Novartis.

    When you hear the name Novartis ($NVS), you probably think of a sprawling Swiss healthcare conglomerate, one of the largest pharmaceutical companies in the world with a hand in everything from prescription drugs to generics. For years, it has been a defensive staple in portfolios, known for its broad diversification and steady dividend.

    But the real story is that Novartis has fundamentally changed. Through major strategic moves, including the recent spinoff of its Sandoz generics division, the company has transformed into a "pure-play" innovative medicines company. The new focus is laser-sharp: developing high-margin, patent-protected blockbuster drugs in cutting-edge therapeutic areas like oncology and cardiology. However, by shedding its more stable businesses, Novartis is now entirely dependent on the high-stakes, high-reward game of drug discovery.
    We're putting the pipeline under the microscope to determine if this leaner, more focused Novartis is poised for a new era of growth or if it has simply traded stability for a much riskier gamble on innovation.


    Created with love by Emil Lazzaroni
    2 new episodes per week, until I can find good companies to hold forever.

    This is not in any way, shape or form financial advice. You are the sole responsible for the action you take after listening to any of my content.

    Always consult a professional before investing.
    Mehr anzeigen Weniger anzeigen
    9 Min.
  • 35. Making money on 50% of payments worldwide

    35. Making money on 50% of payments worldwide
    Jan 18 2026
    For our thirty-fifth episode, we're exploring a company whose logo is in billions of wallets and on millions of storefronts around the globe. It's a business that operates silently in the background of our daily lives, taking a tiny slice of trillions of dollars in global commerce. Like its famous rival, this company is not a bank... [pause] it's a technology network, a secure and vital pipeline for money that makes the modern economy possible. We are talking about Mastercard.

    When you see the Mastercard ($MA) logo on your credit or debit card, you probably think of it as a bank—a company that lends you money. The name is synonymous with the plastic in your wallet, a giant in the world of consumer credit.


    But the real story behind Mastercard is that it's not a bank at all. It takes on zero credit risk. Instead, it's a technology company that operates a massive, global payments network. Think of it as a secure toll road for money; every time you tap, swipe, or click, Mastercard's network connects your bank to the merchant's bank and collects a small, high-margin fee for facilitating the transaction. This has created a powerful duopoly with Visa, benefiting from the massive secular trend of the world moving away from cash. However, this dominance has also attracted intense regulatory scrutiny and a wave of fintech challengers.
    We're swiping right to determine if Mastercard's powerful network effect is strong enough to fend off the threats of regulation and disruption, making it a priceless addition to a growth portfolio.


    Created with love by Emil Lazzaroni
    2 new episodes per week, until I can find good companies to hold forever.

    This is not in any way, shape or form financial advice. You are the sole responsible for the action you take after listening to any of my content.

    Always consult a professional before investing.
    Mehr anzeigen Weniger anzeigen
    9 Min.
  • 34. The company who changed Santa Claus Color to Red

    34. The company who changed Santa Claus Color to Red
    Jan 14 2026
    For our thirty-fourth episode, we're talking about what is arguably the most famous brand ever created. A company whose secret formula is locked away in a vault in Atlanta, a brand that is recognized by an estimated 94% of the world's population. This is the story of how a simple soda fountain drink became a global empire and one of the most perfect business models ever conceived. We are talking about The Coca-Cola Company.

    When you hear the name Coca-Cola ($KO), you think of one of the most iconic and valuable brands in history. It's a global behemoth, selling its famous red-labeled soda in nearly every country on Earth. Most people assume the company is a massive beverage manufacturer, bottling and distributing its products worldwide.
    But the real story behind Coca-Cola's incredible profitability is that it's not primarily a bottler; it's a concentrate company. Coca-Cola creates the secret syrups and sells them to a vast network of independent bottling partners who handle the capital-intensive work of manufacturing and distribution. This creates a fantastically high-margin, asset-light business model. However, this dividend king faces a major headwind: the global consumer shift away from sugary drinks. Can the world's greatest marketing machine adapt to a healthier future?
    We're popping the top to see if Coca-Cola's diversification and brand power can keep its growth from going flat in a changing world.


    Created with love by Emil Lazzaroni
    2 new episodes per week, until I can find good companies to hold forever.

    This is not in any way, shape or form financial advice. You are the sole responsible for the action you take after listening to any of my content.

    Always consult a professional before investing.
    Mehr anzeigen Weniger anzeigen
    9 Min.